Farmacoriflessioni
La tossina botulinica nel trattamento della spasticità in bambini affetti da paralisi cerebrale
Botulinum toxin in the treatment of spasticity in children with cerebral palsy
Paola Maltoni1, Paola Cianci2, Enrico Valletta3, Angelo Selicorni4, Luigi Piccinini5
1UO di Medicina Riabilitativa, Ospedale G.B. Morgagni - L. Pierantoni, AUSL della Romagna, Forlì
2UOC di Pediatria, Ospedale F. Del Ponte, Università Insubria, Varese
3UO di Pediatria, Ospedale G.B. Morgagni - L. Pierantoni, AUSL della Romagna, Forlì
4UO di Pediatria, ASST Lariana, Como
5UOC di Riabilitazione Funzionale, IRCCS “Medea”, Bosisio Parini (Lecco
Giugno 2017 - pagg. 377 -383
Abstract
Botulinum toxin (BoNT) is a powerful rehabilitative instrument used for the focal treatment
of spasticity, described in the literature as efficacious and safe, also during developmental
age, particularly in patients with cerebral palsy. Used in synergy with other available
rehabilitative instruments (therapeutic exercise, orthosis, casting and orthopedic functional
surgery) BoNT can improve these children’s motor functions, when the CNS plasticity enables
wide spaces for learning and also functional modifications. The article describes
“best practice” in patients as well as muscle assessment and evaluation, injection and
dosage techniques, expected results and adverse events. If used in a proper manner,
BoNT has a growing therapeutic importance in the rehabilitative project for the improvement
of children with cerebral palsy.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Eliasson AC, Krumlinde-Sundholm L, Rösblad
B, et al. The Manual Ability Classification
System (MACS) for children with cerebral
palsy: scale development and evidence of
validity and reliability. Dev Med Child Neurol
2006;48:549-54.
2. Bax M, Goldstein M, Rosenbaum P, et al.;
Executive Committee for the Definition of Cerebral
Palsy. Proposed definition and classification
of cerebral palsy, April 2005. Dev Med
Child Neurol 2005;47:571-6.
3. Mutch L, Alberman E, Hagberg B, Kodama
K, Perat MV. Cerebral palsy epidemiology:
where are we now and where are we going?
Dev Med Child Neurol 1992;34:547-51.
4. Bax MC. Teminology and classification of
cerebral palsy. Dev Med Child Neurol 1964;
6:295-7.
5. Ferrari A, Cioni G. Le forme spastiche della
paralisi cerebrale infantile. Guida all’esplorazione
delle funzioni adattative. Springer, 2005.
6. Fabbri M, Leodori G, Fernandes RM, et al.
Neutralizing Antibody and Botulinum Toxin
Therapy: A Systematic Review and Metaanalysis.
Neurotox Res 2016;29:105-17.
7. Mills PB, Finlayson H, Sudol M, O’Connor
R. Systematic review of adjunct therapies to
improve outcomes following botulinum toxin
injection for treatment of limb spasticity. Clin
Rehabil 2016;30:537-48.
8. Novak I, Mcintyre S, Morgan C, et al. A systematic
review of interventions for children
with, cerebral palsy: state of evidence. Dev
Med Child Neurol 2013;55:885-910.
Corrispondenza: paola.maltoni@auslromagna.it